ZOLADEX 10.8 mg is administered subcutaneously every 12 weeks, with specific protocols for combination therapy.

Subcutaneous Depot Dosing Protocol

The standard dose is a 10.8 mg implant injected subcutaneously into the anterior abdominal wall below the navel every 12 weeks. For Stage B2-C prostate cancer, therapy begins with a 3.6 mg dose followed by 10.8 mg after 28 days, concurrent with flutamide and radiation. Adherence to the 12-week schedule is critical, though minor delays are permissible. No dose adjustments are required for renal/hepatic impairment, geriatric patients, or body weight variations. Administration requires aseptic technique to avoid vascular injury, particularly in anticoagulated or low-BMI patients. The syringe’s safety mechanism reduces needlestick risks. Women are excluded from the 10.8 mg regimen due to inadequate estrogen suppression.